SCHEMBL6221420

SCHEMBL6221420

COC(=O)CNCC(=O)Nc1cccc(-c2nc(SC)nc3sc(C(=O)NC(C)(C)C)c(N)c23)c1

nearest known ligand 0.69

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
LHCGR P22888 18/20 0.69
TSHR P16473 2/20 0.69
FSHR P23945 5/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5030974 0.90 LHCGR (0.53) LHCGRTSHRFSHR
SCHEMBL6220667 0.89 LHCGR (0.53) LHCGRTSHRFSHR
SCHEMBL14285229 0.88 LHCGR (0.73) LHCGRTSHRFSHR
SCHEMBL6221749 0.87 LHCGR (0.67) LHCGRTSHRFSHR
SCHEMBL5028843 0.87 LHCGR (0.72) LHCGRTSHRFSHR
SCHEMBL4425902 0.87 LHCGR (0.78) LHCGRTSHRFSHR
SCHEMBL6225588 0.87 LHCGR (0.55) LHCGRTSHRFSHR
SCHEMBL6222004 0.87 LHCGR (0.68) LHCGRTSHRFSHR
SCHEMBL5026188 0.87 LHCGR (0.51) LHCGRTSHRFSHR
SCHEMBL6222712 0.86 LHCGR (0.69) LHCGRTSHRFSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1427734-B1 GLYCINE-SUBSTITUTED THIENO[2,3-d]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY AKZO NOBEL NV (NL) 2005-11-09 EP claimed
EP-1427734-B1 GLYCINE-SUBSTITUTED THIENO[2,3-d]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY AKZO NOBEL NV (NL) 2005-11-09 EP disclosed
US-20040180907-A1 Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity MERCK SHARP & DOHME B.V. (NL) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180907-A1 Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity FSHR, GNRHR, LHCGR LHCGR 3/4885TSHR 45/4885FSHR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.